The Swiss proteomics company Biogynosys recently announced it will open its first North American office in Greater Boston this year.

This follows an announcement earlier this year that the company had received funding from a corporate investment fund to establish operations in the United States and develop new workflows and products for high-content protein analysis. The Massachusetts Life Sciences Center has worked closely with the company to assist with the selection of their U.S. location.

“We welcome Biognosys to Massachusetts and look forward to having them be a part of our thriving life sciences community,” Gov. Charlie Baker said in a statement. “Massachusetts is a great place for international life sciences companies that are looking to enter the U.S. market to locate and do business.”

“The Boston area is perhaps the most dynamic biopharma cluster in the United States today,” Stephan van Sint Fiet, Biognosys CCO, said in a statement. “The proximity to so many great life science companies, the support from organizations such as the MLSC and the small time zone difference to Europe make Boston an ideal location for a European biotech company looking to establish U.S. operations.”